The use of nivolumab, a human IgG4 MoAb which blocks the interaction with PD-L1 and PD-L2 by binding to the PD-1 receptor on activated immune cells, was approved by FDA in 2016 for the treatment of relapsed or progressed Hodgkin lymphoma [52]. This evidence concerns the gene CD274 and Hodgkins lymphoma.